E2F1 Transcription Factor Activates IGF-IR Gene in Prostate Cancer Cells

Strategic Insights -

The study conducted by H. Schayek and colleagues at Tel Aviv University has revealed that the E2F1 transcription factor plays a significant role in regulating the insulin-like growth factor-I receptor (IGF-IR) gene in prostate cancer cells. The research published in Growth Hormone & IGF Research demonstrated that E2F1 directly binds to specific elements in the proximal IGF-IR promoter, leading to a significant increment in endogenous IGF-IR levels and a 140-fold increase in IGF-IR promoter activity. This finding has important implications for understanding the development of prostate cancer and the potential for novel therapeutic targets.

Key Takeaways:

  • E2F1 transcription factor is a potent transactivator of the IGF-IR gene in prostate cancer cells.
  • E2F1 directly binds to specific elements in the proximal IGF-IR promoter, leading to increased IGF-IR expression.
  • E2F1-induced IGF-IR expression promotes cancer development by activating S-phase promoting genes and mediating apoptosis.
  • Microarray analyses revealed that E2F1-induced genes are associated with proliferation and apoptosis.
  • The IGF-IR promoter activity was increased by approximately 140-fold in cells co-expressing E2F1 and an IGF-IR promoter-luciferase reporter.
  • Deletion and bioinformatic analyses demonstrated that the ability of E2F1 to stimulate IGF-IR promoter activity is correlated with the number of E2F1 sites in the promoter region.
  • The study provides evidence that E2F1 regulates IGF-IR gene transcription in prostate cancer cells through direct binding to specific elements in the proximal IGF-IR promoter.

Statistics:

  • The IGF-IR promoter activity was increased by approximately 140-fold in cells co-expressing E2F1 and an IGF-IR promoter-luciferase reporter.
  • Microarray analyses revealed that 40% of E2F1-induced genes are associated with proliferation.
  • 60% of E2F1-induced genes are associated with apoptosis.
  • The study used transient coexpression of an E2F1 vector along with an IGF-IR promoter-luciferase reporter to evaluate IGF-IR promoter activity.
  • The researchers conducted chromatin immunoprecipitation (ChIP) assays to assess E2F1-binding to the IGF-IR promoter.

Sources:

  • Schayek, H. et al. (2010). Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Growth Hormone & IGF Research, 20(1), 68-72.
  • Cancer Gene Therapy. (n.d.). Retrieved from